Staphylococcus aureus small colony variants: rate of selection and MIC values compared to wild-type strains, using ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin  by Schmitz, Franz-Josef et al.
376 Clinical Microbio logy and Infection, Volume 5 Number  6 ,  June 1999 
3. German JC, Flores JH, Chiesura G, et al. Estrongiloidasis fatal 
en paciente inmunodeprimido pos-trasplante renal. Rev Hosp 
Clin Fac Med Sao Paulo 1992; 47: 31-3. 
4. Celedon JC, Mathur-Wagh AU, Fox J, Garcia R, Wiest PM. 
Systemic strongyloidiasis in patients infected with the human 
immunodeficiency virus. A report of 3 cases and review of the 
literature. Medicine (Baltimore) 1994; 73: 256-63. 
5. Lessnau K-D, Can S, Talavera W. Disseminated Strongyloides 
stercoralis in human immunodeficiency virus-infected patients. 
Treatment failure and review of the literature. Chest 1993; 104: 
119-22. 
6. Pelletier LL. Chronic strongyloidiasis in World War I1 Far East 
ex-prisoners of war. Am J Trop Med Hyg 1984; 33: 55-61. 
7. Grove DI. Strongyloidiasis in Allied ex-prisoners of war in 
Southeast Asia. Br Med J 1980; 280: 598-601. 
8. DeVault GA, King JW, Rohr MS, Landreneau MD, Brown 111 
ST, McDonald JC. Opportunistic infections with Strongyloides 
stercorulis in renal transplantation. Rev Infect Dis 1990; 12: 
9. Harada Y, Mori 0. A new method for culturing hookworm. 
Yonago Acta Med 1955; 1: 177-9. 
10. Garcia LS, Bruckner DA. Adhtional techniques for stool 
examination. Diagnostic m e d d  parasitology. Washington DC: 
American Association for Microbiology, 1997: 65241, 
653-71. 
11. Grove DI. Treatment of strongyloimasis with thiabendazole: an 
analysis oftoxicity and effectiveness. Trans R SOC Trop Med Hyg 
1982; 76: 114-18. 
12. Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human 
strongyloidiasis and other intestinal helminths. Am J Trop Med 
Hyg 1989; 40: 304-9. 
13. Datry A, Hilmarsdottir I, Mayorga-Sagastume R, et al. Treat- 
ment of Strongyloides stercoralis infection with ivermectin 
compared with albendazole: results of an open study of 60 cases. 
Trans R SOC Trop Med Hyg 1994; 88: 344-5. 
14. Torres JR,  Isturiz R, Murillo J, Guzmin M, Contreras R. 
Eacacy of ivermectin in the treatment of strongyloidiasis 
complicating AIDS. Clin Infect Dis 1993; 17: 9OC-2. 
15. Gann PH, Neva FA, Gam AA. A randomized trial ofsingle- and 
two-dose ivermectin versus thiabendazole for treatment of 
strongyloidiasis. J Infect Dis 1994; 169: 107. 
16. Schad GA. Cyclosporin may eliminate the threat of over- 
whelming strongyloidiasis in immunosuppressed patients. 
J Infect Dis 1986; 153: 178. 
17. Nolan TJ, Schad GA. Tacrolimus allows autoinfective develop- 
ment of the parasitic nematode Strongyloides stercoralis. Trans- 
plantation 1996; 62: 1038. 
Stuphylococcus uureus small colony variants: rate of selection and MIC values 
compared to wild-type strains, using ciprofloxacin, ofloxacin, levofloxacin, 
sparfloxacin and moxifloxacin 
Clin Microbiol Infect 1999; 5:  376-378 
Franz-Josef Schmitz','*, Chvistof von E g 3 ,  Mechtlzild Gondolf I ,  Ad C. Fluit ', Jan Verhoef', 
Georg Peters3, Ulrich Hadding I ,  Hans-Peter Heinx', and Mark E. Jones2 
'Institute for Medical Microbiology and Virology, Heinrich-Heine University, UniversitatstraRe 1,  
D-40225 Dusseldorf', Germany; 2Eijkman-Winkler Institute for Medical Microbiology, Utrecht 
University, Utrecht, The Netherlands; 31nstitute for Medical Microbiology, Westfalische Wilhelms 
University Munster, Germany 
*Tel: +49 211 811 2460 Fax: +49 211 811 5323 
E-mail: schmitfy&uni-duesseIdorf.de 
Accepted 9 October 1998 
Small colony variants (SCVs) represent minority sub- 
populations of Staphylococcus aureus that grow slowly 
(>72 h) on routine media, yielding small, non-pig- 
mented, non-hemolytic colonies. Although S. aweus 
SCVs have been recognized for many years [l-31, the 
connection between this phenotype and persistent 
recurrent infections has only recently been appreciated. 
Clinical and laboratory-generated S. aureus SCVs are 
frequently auxotrophic for menadione or hemin, two 
compounds required in the biosynthesis of mena- 
quinone and cytochromes, components of the electron 
transport chain. The subsequent decrease in electron 
transport activity in SCVs may account for their 
resistance to a variety of antibiotics and other anti- 
staphylococcal compounds, such as protamine, some 
antibiotics, and platelet microbiocidal proteins, and also 
provide a mechanism for their persistence within host 
tissues 14-61. 
It is well known that S. aureus SCVs can be derived 
from clinical isolates both in vitro and in vivo following 
exposure to aminoglycosides and p-lactam antibiotics 
[1,2,4,5]. Mitsuyama et al. recently described the emer- 
gence of SCVs after exposure of wild-type parent 
strains to an MIC concentration of the fluoroquinolone 
pazufloxacin [7] .  Emergent SCVs were half as suscep- 
tible to pazufloxacin and ciprofloxacin as dd-type S. 
aureus. Reduced susceptibilities of SCVs to these 
compounds were not a result of mutations in gyrA, 
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gyrB, $A or grlB, or efflux via NorA, but rather were 
mediated by decreased fluoroquinolone uptake, perhaps 
as a result of permeability changes in the cell wall. 
Little is known about the ability of different quino- 
lone compounds to select for SCVs in S. aureus or the 
MICs of these antibiotics for the SCV isolates subse- 
quently selected. In this study we investigated the 
spontaneous mutation rate and frequency of SCV 
emergence in S. aureus isolates exposed to five different 
fluoroquinolones (ciprofloxacin, ofloxacin, levoflox- 
acin, sparfloxacin and moxifloxacin). The in vitro 
activities of these quinolone compounds were also 
measured against SCVs and sibling strains with a 
normal phenotype. 
Two clinical isolates of S. aureus (i57, methicillin 
susceptible, and S78, methicillin resistant) were used to 
investigate spontaneous mutation rates and the fre- 
quencies of SCV emergence when they were exposed 
to each of the five quinolone compounds. Two control 
isolates were also used in this study, I10 (a stable SCV 
generated by interrupting hem& the hemin bio- 
synthetic gene in S. aweus, by inserting an ermB 
cassette), and A2 (a stable strain of I10 complemented 
with an intact h e m B  [6], resulting in a wild-type 
phenotype). All four isolates were ciprofloxacin suscep- 
tible (Table 1). 
Mutant colonies with higher MIC values than 
those of the parent strains were obtained by spreading 
109-101' colony-forming units (CFUs) per mL of each 
of the four test isolates over agar plates containing, in 
parallel, two-fold and four-fold MICs of each of the 
compounds tested. IsoSensitest agar plates were used 
for i57 and S78, while trypticase soy (TSA) agar plates 
supplemented with 2.5 mg/l, of erythromycin (and 10 
mg/L of chloramphenicol to select for the comple- 
menting plasmid in strain A2) were used for the control 
strains. Following overnight incubation at 37OC, the 
number of colonies growing was determined. The 
frequency of appearance of mutants with raised MICs 
was calculated as the ratio of mutants arising after 
overnight incubation to the number of CFUs originally 
inoculated. This experiment was repeated four times 
for each of the five fluoroquinolones tested. SCVs 
selected from isolates i57, S78 and A2 were recognized 
and characterized as previously described [4,5]. In 
brief, isolates considered to be stable SCVs were grown 
on TSA agar with disks containing 2.0 pg of 
menadione or 20 pg of hemin, in the presence of 5% 
COZ, to test for auxotrophism for these compounds. 
Gram stain characteristics, hemolytic activity, coagulase 
production and susceptibility tests for lysostaphin were 
evaluated by standard procedures. From one agar plate, 
for each strain, and for each of the fluoroquinolones 
tested, 25 isolates demonstrated to be SCVs and 25 
isolates with normal phenotypes were randomly 
selected for MIC testing. In addition, we paralleled our 
MIC studies using four S. aureus SCV isolates shown to 
fulfil the microbiological definition of SCV, derived 
from patients each of whom had previously been 
treated for osteomyelitis with gentamicin-impregnated 
beads. In each case, clinical SCV isolates were isolated 
concomitantly with normal methicillin-susceptible 
wild-type organisms shown to be clonally identical as 
determined by pulsed-field gel electrophoresis [8]. The 
MIC values for ciprofloxacin, ofloxacin, levofloxacin, 
sparfloxacin and moxifloxacin were determined by 
both broth microdilution and agar dilution methods, 
using an inoculum of lo5 CFU/mL, with results being 
analyzed after 48 h of incubation at 35°C. 
Following exposure ofisolates i57, S78, A2 and I10 
to two and four times the MIC of each test drug, the 
spontaneous mutation rates for the appearance of 
colonies with higher MICs were in the range of lop5 
to lop7 for ciprofloxacin, lo-' to I O P  for ofloxacin 
and levofloxacin, and lo-* to lop9 for sparfloxacin and 
moxifloxacin. Thus, resistance against the newer fluoro- 
Table 1 Quinolone susceptibility of randomly selected mutants of S. aureus strains i57, S78, A2 and I10 after exposure to 
four times the MIC of ciprofloxacin and moxifloxacin 
MIC of mutants (mg/L) 
MIC of parent strain (mg/L) Ciprofloxacin Moxifloxacin 
Parent - No. of Colony 
strain Ciprofloxacin Moxifloxacin mutants identification Range MICso MIC9o Range MICso MIC9o 
157 0.25 10.03 25 scv 1-2 1 2 0.125-0.5 0.25 0.5 
25 Non-SCV 1-2 1 2 0.1254.5 0.25 0.5 
S78 0.25 10.03 25 scv 1-2 1 2 0.125-0.5 0.25 0.5 
25 Non-SCV 1-2 I 2 0.1254.5 0.25 0.5 
110a 0.125 0.06 25 scv 0.5-2 1 2 0.25-1 0.5 1 
A2b 0.125 0.015 25 scv 0.5-2 1 2 0.25-1 0.5 1 
25 Non-SCV 0.5-2 1 2 0.25-1 0.5 1 
a 110, a stable SCV a hemB mutant. 
hA2, a normal phenotype; hemB-complemented I10 isolate. 
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quinolones such as sparfloxacin and moxifloxacin 
develops less frequently compared to other quinolones 
tested. Selection with two and four times the MIC led 
to the emergence of SCVs in the wild-type parent 
strains i57 and S78 as well as in the plasmid-comple- 
mented mutant A2, with each of the five fluoroquino- 
lones tested. Mean percentage values of the frequency 
of SCV isolation from four independent experiments 
were as follows, for ciprofloxacin, ofloxacin, levoflox- 
acin, sparfloxacin and moxifloxacin respectively; for 
strain i57,37%, 33%, 43%, 38% and 40%; for strain S78, 
65%, 72%, 49%, 50% and 35%; and for strain A2,41%, 
38%, 43%, 35% and 33%. Thus, the frequency of SCV 
isolation from these three strains ranged between 33% 
and 72%, with no significant difference between any of 
the antibiotics tested (p > 0.1). 
In contrast to Mitsujama et al[7] (who used 0.25, 
1.0 and 4.0 times the MIC to select for mutants), we 
were unable to find any differences in MIC values 
of any of the quinolones tested between randomly 
selected resistant SCVs and sibling strains with a normal 
phenotype, after exposure to two and four times the 
MIC, independent of the susceptibility test method 
used. None of the SCVs or normal wild-type organ- 
isms had MIC values above 2 mg/L for any of the drugs 
tested. Table 1 shows the range and MIC50 and MI& 
values for ciprofloxacin and moxifloxacin, the least 
active and most active of the compounds tested, against 
mutants selected with four times the MIC. Comparable 
data were obtained for mutants selected with two times 
the MIC. In line with this observation, there were also 
no differences in quinolone MIC values between the 
four clinically derived SCVs (data not shown). The 
differences between our study and that reported 
by Mitsujama et a1 with regard to the ability of 
quinolones to select for stable SCVs may be due to the 
phenomenon being strain and/or quinolone depend- 
ent, as pazufloxacin was used as a study compound [7]. 
Ciprofloxacin showed the highest MIC values, 
followed by ofloxacin, levofloxacin, sparfloxacin and 
moxifloxacin as the most active with the lowest MIC 
values (Table 1). This is in accordance with previous 
investigations, in which moxifloxacin was the most 
active compound, in response to all characterized 
mutations in grlA, grlB, gyrA and gyrB in 1 16 unrelated 
clinical S. aureus isolates [9]. 
The development of quinolone resistance in S. 
aureus requires multiple and stepwise mutations, with 
mutations in grlA preceding mutations in gyrA [lo]. 
Therefore, we were not able to select fluoroquinolone- 
resistant SCVs or strains with normal phenotype using 
only one overnight incubation at two or four times the 
MIC. 
By comparing SCVs to strains with a wild-type 
phenotype, our study offers the possibility to investigate 
the effect that a lower electrochemical gradent across 
the cell membrane has on susceptibility to both old and 
new fluoroquinolones. In contrast to susceptibility to 
aminoglycoside compounds, our data suggest that the 
lower electrochemical gradent across the cell mem- 
brane has no effect on fluoroquinolone susceptibility. 
While quinolone monotherapies are not generally used 
in the treatment of infections caused by S. aureus, they 
are often used as empirical therapies for respiratory tract 
infections, of which a proportion wdl be caused by S. 
aureus or present as part of a mixed infection, partic- 
ularly for those that are hospital acquired. In such 
instances, exposure to quinolone compounds clearly 
provides an opportunity for the selection of SCVs 
which may play a role in recurrent infections. 
In summary, moxifloxacin is the most active com- 
pound tested, with the lowest spontaneous mutation 
rate. Selection with two and four times the MIC led to 
the emergence of SCVs with all five fluoroquinolones 
tested. Whde the selection of SCVs seems to be strain 
dependent, the lower electrochemical gradient across 
the cell membrane in SCVs has no effect on fluoro- 
quinolone susceptibility. 
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